Adv Modelling & Sim Gene Therapy Lead - UCB S.A. - Braine-l'Alleud

UCB S.A.

Région

N/A

Make your mark for patients.

We’re here because we want to build the future and transform patients’ lives for the better.

At UCB, our people are our experiences and achievements, our passion and drive. That’s why we’re looking for talented individuals with diverse backgrounds and experiences - not just the best and brightest, but those who care about making a meaningful difference in the lives of patients. We promote an environment of diversity, openness, and respect where people can make valuable contributions.

An exciting journey lies ahead. Will you join us in pushing the boundaries of what’s possible?


In this key role he/she will serve as an internally and externally recognised Advanced Modelling and Simulation Expert /Pharmacometrician working within a matrix team supporting early (pre-POC) and late phase (post-POC) projects to deliver and apply quantitative solutions to drive the delivery of the translational and clinical development plan and when required represent modelling and simulation in project teams and regulatory meetings.


Working mainly outside the classical clinical/project team frame-work, dealing directly with key individuals (Quantitative Clinical Pharmacologist, Exploratory Statistician, Biomarkers and Therapeutic Experts) to scope the key question/concept, plan a solution, and lead its execution and delivery, providing an answer.


In particular, he/she will provide specialized pharmacometric expertise to multiple projects, and will work within a dedicated team along with an external network of experts to support the delivery of analyses, enhance project impact, develop and apply new methodologies and solutions, whilst remaining at the cutting edge in terms of expertise. He/she is expected to provide leadership and help junior members in the team


Key Criteria: Expertise, Strategy, Execution and Communication


Expertise

  • Knowledge of PK and PK/PD models
  • Knowledge of relevant software (NONMEM, R, others)
  • Knowledge of model development / model optimization (selecting structural model, covariate analysis, graphical and statistical assessment of data and output)
  • Knowledge of clinical trial optimization
  • Knowledge of relevant guidances
  • Able to introduce new methodology
  • Either strong mathematical / statistical background with sufficient physiological / pharmacological knowledge or strong physiological / pharmacological background with sufficient mathematical / statistical knowledge


Strategy

  • Able to set up a M&S development plan
  • Advice on optimal use of M&S in drug development
  • Advice on study design to ensure optimal data for M&S
  • Set priorities (essential to have, good to have, nice to have)


Execute

  • Able to perform M&S independently
  • Reporting of results within a regulatory frame-work
  • Work with CROs with a partnership/collaboration mindset


Communicate

  • Able to communicate with non-experts to ensure we deliver what is expected
  • Able to explain results to experts and non-experts
  • Able to present at conferences


About us.

UCB is a global biopharmaceutical company, focusing on neurology and immunology. We are around 7,600 people in all four corners of the globe, inspired by patients and driven by science.

At UCB, everything we do start with a simple question: “How will this create value for people living with severe disease?”. We are on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. We want to ensure the creation of patient value, now and into the future, while contributing to a society where a population of 8 billion people and more should be able to live a good life within limited resources of one planet.


UCB and its subsidiaries encourage diversity and inclusion in the workplace; we are an Equal Opportunity Employer. We do not discriminate on the basis of race/color/religion/sex/national origin/veteran/disability/age/sexual orientation/gender identity.

UCB S.A.

Société

UCB S.A.